Who is eligible for clinical trial NCT06095102?

Participants must meet protocol criteria for Plaque Psoriasis. Confirm exact inclusion and exclusion requirements with the study coordinator.

Does clinical trial NCT06095102 provide travel or cost reimbursement?

Check with the site coordinator at the participating facility for travel and lodging stipend availability, and for which routine-care costs are covered.

🏛️ Verified NIH Record • Updated 2026-08-27

A Study of JNJ-77242113 for the Treatment of Participants With Plaque Psoriasis Involving Special Areas (Scalp, Genital, and/or Palms of the Hands and the Soles of the Feet) (NCT06095102)

🔵 Active, Not Recruiting Phase3 💊 Investigational Drug / Biologic Sponsor: Janssen Research & Development, LLC

🩺 Plain-English Summary (8th-Grade Level)

The purpose of the study is to see how effective JNJ-77242113 is in participants with plaque psoriasis affecting special areas (scalp, genital, and/or palms of the hands and the soles of the feet).

Who can join: To join this study, participants generally need to meet the listed inclusion criteria (5 items) and avoid the listed exclusions (6 items).

Location: Center for Dermatology and Plastic Surgery — Scottsdale, Arizona

📋 "Do I Qualify?" — 1-Minute Self Screener

Instant Checklist

Check every box below. If you can check all of them, you may meet the study's basic screening requirements (final eligibility is confirmed by the site team).

Diagnosis of plaque psoriasis, with or without psoriatic arthritis (PsA), for at least 26 weeks prior to the first administration of study intervention
Candidate for phototherapy or systemic treatment for plaque psoriasis
Need to meet criteria: Total body surface area (BSA) greater than or equal to (\>=)1 percent (%) at screening and baseline, and investigator global assessment (IGA) (overall) \>=2 at screening and baseline and at least one of the following: scalp-specific investigator global assessment (ss-IGA) score \>=3 at screening and baseline, and/or static physician's global assessment of genitalia (sPGA-G) \>=3 at screening and baseline, and/or physician's global assessment of hands and feet (hf-PGA) score \>=3 at screening and baseline
Failed to respond to at least 1 topical therapy (example, corticosteroids, calcineurin inhibitors, and/or vitamin D analogs) used for treatment of psoriasis
Confirmation of plaque psoriasis in a non-special area (example, areas excluding scalp, genital, palmoplantar) at screening and baseline

Usually NOT eligible if any of the following apply:

Exclusion Criteria:
Nonplaque form of psoriasis (example, erythrodermic, guttate, or pustular)
Dermatoses other than plaque psoriasis (such as contact dermatitis) or palmoplantar pustulosis of the palmoplantar area (if hf-PGA \>=3 at baseline)
Current drug-induced psoriasis (example, a new onset of psoriasis or an exacerbation of psoriasis from beta blockers, calcium channel blockers, or lithium)
A current diagnosis or signs or symptoms of severe, progressive, or uncontrolled renal, liver, cardiac, vascular, pulmonary, gastrointestinal, endocrine, neurologic, hematologic, rheumatologic, psychiatric, or metabolic disturbances
Known allergies, hypersensitivity, or intolerance to JNJ-77242113 or its excipients

🔍 Extracted verbatim from the official NIH eligibility criteria. Always confirm with the study coordinator.

📍 All Participating Trial Locations (90 Sites)

Center for Dermatology and Plastic Surgery — Scottsdale, Arizona
Johnson Dermatology — Fort Smith, Arkansas
California Dermatology & Clinical Research Institute — Encinitas, California
Forcare Clinical Research Inc — Tampa, Florida
Hamilton Research LLC — Alpharetta, Georgia
Arlington Dermatology — Rolling Meadows, Illinois
Dundee Dermatology — West Dundee, Illinois
Dawes Fretzin Clinical Research Group LLC — Indianapolis, Indiana
Indiana Clinical Trial Center — Plainfield, Indiana
Dermatology and Advanced Aesthetics — Lake Charles, Louisiana
Allcutis Research 1 — Beverly, Massachusetts
Hamzavi Dermatology — Fort Gratiot, Michigan
Minnesota Clinical Study Center — New Brighton, Minnesota
MediSearch Clinical Trials — Saint Joseph, Missouri
Skin Specialists — Omaha, Nebraska
Schweiger Dermatology Group — East Windsor, New Jersey
Optima Research — Boardman, Ohio
Oregon Dermatology and Research Center — Portland, Oregon
Paddington Testing Co, Inc. — Philadelphia, Pennsylvania
University of Pittsburgh Medical Center — Pittsburgh, Pennsylvania
Arlington Research Center, Inc. — Arlington, Texas
Center for Clinical Studies 1 — Houston, Texas
Austin Institute for Clinical Research — Pflugerville, Texas
Progressive Clinical Research — San Antonio, Texas
Dermatology Clinical Research Center of San Antonio — San Antonio, Texas

💰 Cost, Insurance & Patient Rights

100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

🏛️ View Official NIH Record ↗